Greg Bonfiglio is the founder and managing partner of Proteus, LLC. Greg was an early investor in the field of stems cell and regenerative medicine (RM), and he continues to actively invest in the field. Greg is the chair of the board of the Centre for Commercialization of Regenerative Medicine, an RM translation centre in Toronto. He is a member of the ISSCR and is on their advisory board as well as their finance committee. He also is a member of the ISCT. Greg and his colleagues are experts regarding challenges inherent in commercializing RM technologies.
Greg has served on the boards of several RM companies, including VistaGen Therapeutics (in vitro tools from hESCs), California Stem Cell (hESC tools & therapeutics), and StemCyte, Inc. (cord blood storage & therapeutics). Greg is a frequent speaker at RM conferences, and in 2013, he was named a Top 50 Stem Cell Influencers in the world (ranked 14th).
From 2000–2005, Greg was a general partner with Anthem Venture Partners, an early-stage venture fund in California. Greg led Anthem’s investment in advanced cell technology in 2000, helping to take the company public in 2005. Greg also led Anthem’s investment in Corus Pharma and helped engineer the sale of Corus to Gilead.